Trevi Therapeutics Stock Investor Sentiment

TRVI Stock  USD 2.88  0.04  1.37%   
Under 67% of Trevi Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that many investors are alarmed at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
  

Trevi Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
few days ago at thelincolnianonline.com         
Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc.
news
few days ago at finance.yahoo.com         
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Yahoo News
over a week ago at news.google.com         
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow
Google News at Macroaxis
over a week ago at news.google.com         
Trevi Therapeutics, Inc. Receives 7.43 Average PT from Brokerages - MarketBeat
Google News at Macroaxis
over a week ago at news.google.com         
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences - Quantisnow
Google News at Macroaxis
over two weeks ago at insidermonkey.com         
Trevi Therapeutics, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over two weeks ago at finance.yahoo.com         
Trevi Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Increased Losses and ...
Yahoo News
over two weeks ago at gurufocus.com         
Trevi Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Increased Losses and ...
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Yahoo News
over two weeks ago at seekingalpha.com         
Trevi Therapeutics EPS of -0.13 misses by 0.02
seekingalpha News
over two weeks ago at thelincolnianonline.com         
Trevi Therapeutics Set to Announce Quarterly Earnings on Wednesday
news
over a month ago at gurufocus.com         
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Trevi Therapeutics Given Buy Rating at HC Wainwright
news
over a month ago at finance.yahoo.com         
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Yahoo News
over a month ago at finance.yahoo.com         
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Yahoo News
Far too much social signal, news, headlines, and media speculation about Trevi Therapeutics that are available to investors today. That information is available publicly through Trevi media outlets and privately through word of mouth or via Trevi internal channels. However, regardless of the origin, that massive amount of Trevi data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Trevi Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Trevi Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Trevi Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Trevi Therapeutics alpha.

Trevi Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 3863 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/03/2024
2
Disposition of 4219 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/06/2024
3
Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/09/2024
4
Trevi Therapeutics, Inc. Given Average Rating of Buy by Analysts - MarketBeat
09/24/2024
5
Acquisition by James Cassella of 400000 shares of Trevi Therapeutics at 3.34 subject to Rule 16b-3
09/30/2024
6
Trevi Therapeutics Provides Update on Haduvios Clinical Development Program
10/03/2024
7
Trevi Therapeutics Inc Q2 2024 Earnings Call Highlights Navigating Financial Challenges ...
10/09/2024
8
Trevi Therapeutics Given Buy Rating at HC Wainwright
10/22/2024
9
Trevi Therapeutics EPS of -0.13 misses by 0.02
11/06/2024
10
Trevi Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Increased Losses and ...
11/07/2024
11
Trevi Therapeutics, Inc. Receives 7.43 Average PT from Brokerages - MarketBeat
11/13/2024
12
Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc.
11/22/2024

Complementary Tools for Trevi Stock analysis

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios